Sartorius AG

XETRA: SRT.DE

Stock price

195 EUR

(+Infinity%) NaN day

Earnings Call Takeaways

Call date: Feb 3, 2026

1) Strategy & Leadership - CEO Michael Grosse expressed gratitude for the team's dedication and highlighted a smooth transition into his role. - The company focused on operational management amidst a challenging environment, achieving improved financial performance. - Sartorius aims for sustainable innovation-led growth, emphasizing investments in R&D and production capacity.

2) Financial & Segment Results - Full-year sales revenue increased by 7.6% in constant currencies, reaching slightly over EUR 3.5 billion. - Underlying EBITDA rose by 11.2% to EUR 1.052 billion, with a margin of 29.7%. - Bioprocess Solutions saw 9.5% growth in sales, driven by mid-teens growth in consumables, while Lab Products & Services remained flat at 0.2% growth. - The Americas and APAC regions both grew by 8.9%, with EMEA showing almost 6% growth.

Metric 2025 Results
Sales Revenue EUR 3.5 billion
Underlying EBITDA EUR 1.052 billion
EBITDA Margin 29.7%
Bioprocess Solutions Growth 9.5%
Lab Products Growth 0.2%

3) Problems / Headwinds - Equipment sales continued to be soft, although stabilizing in H2 2025. - The company faced headwinds from U.S. dollar weakness and tariffs, impacting reported sales growth. - The ongoing cautious investment activities from core customers contributed to a challenging market environment.

4) Operational or Product Plans - Sartorius launched several new products, including a PFAS-free filtration solution and a continuous bioprocessing platform. - The company completed expansions in Aubagne and Germany and is constructing a new site in South Korea to enhance manufacturing capabilities. - The acquisition of MATTEK is expected to contribute positively to growth, particularly in advanced 3D cell models.

5) Guidance & Outlook / Investor Angle - For 2026, Sartorius expects sales growth of 5% to 9% and an underlying EBITDA margin slightly above 30%. - The guidance reflects cautious optimism, with expectations for continued growth in Bioprocess Solutions and stabilization in Lab Products & Services. - The company anticipates that equipment sales will remain stable, with growth in consumables expected to be in the low teens, excluding China.

Bottom line: Sartorius demonstrated strong operational performance in 2025, positioning itself for sustainable growth in 2026 despite ongoing market challenges. The company’s focus on innovation and strategic investments, coupled with a solid order book, supports a positive outlook for shareholders.

Sartorius AG (SRT.DE) earnings call summaries

Read Sartorius AG (SRT.DE) quarterly earnings call takeaways covering reported results, management commentary, business priorities, guidance, and material risks.

Compare recent calls to follow changes in management expectations and connect qualitative updates with the company’s fundamental performance.